Skip to content
Screener

Biohaven BHVN Current ratio

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.4×+0.1×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
21×+5.9×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
15.7×-7.0×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-1.0×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
10.6×+3.4×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
19.3×+6.9×

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Based on the most recent quarter.

The source filing: Biohaven’s 10-Q, filed May 4, 2026. Open the filing →

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045

FAQ

What is Biohaven's current ratio?
Biohaven (BHVN) reported current ratio of 7.4× in Q1 2026.
How has Biohaven's current ratio changed year-over-year?
Biohaven's current ratio increased by 217.4% year-over-year, from 2.3× to 7.4×.
What is the long-term trend for Biohaven's current ratio?
Over 4 years (2021 to 2025), Biohaven's current ratio has grown at a 8.9% compound annual growth rate (CAGR), from 2.3× to 3.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Biohaven's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude